Stay updated with breaking news from Roberti blum. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Dana Investment Advisors Inc. theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Cytokinetics (NASDAQ:CYTK – Get Free Report) issued its earnings results on Tuesday. The biopharmaceutical company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($1.03) by ($0.35), Briefing.com reports. The company had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $7.62 million. The firm’s quarterly revenue was […]
Cytokinetics Reports Fourth Quarter 2023 Financial Results streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated CYTK today announced that Robert I. Blum, President and Chief…
Moody Aldrich Partners LLC increased its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 5.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 94,448 shares of the biopharmaceutical company’s stock after purchasing an additional 5,172 shares during […]
UBS Group downgraded shares of Cytokinetics (NASDAQ:CYTK – Free Report) from a buy rating to a neutral rating in a report published on Wednesday, Marketbeat.com reports. They currently have $92.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $61.00. Other research analysts also recently issued research reports about the […]
UBS Group downgraded shares of Cytokinetics (NASDAQ:CYTK – Free Report) from a buy rating to a neutral rating in a research note published on Wednesday, Marketbeat.com reports. The brokerage currently has $92.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $61.00. Other research analysts also recently issued reports about […]
UBS Group downgraded shares of Cytokinetics (NASDAQ:CYTK – Free Report) from a buy rating to a neutral rating in a research note released on Wednesday, Marketbeat Ratings reports. UBS Group currently has $92.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $61.00. A number of other research analysts also […]
Robert I. Blum Sells 12,500 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.